$11.25
Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis
Overview
52-week range
$2.88
$18
55% of range
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Earnings trends
Implied volatility — last 90 days
No IV snapshots yet for PLRZ.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.